Results 161 to 170 of about 54,854 (258)

Therapeutic Gene Editing: DNA Repair Pathways, Emerging Editors, and Clinical Progress

iNew Medicine, Volume 2, Issue 1, March 2026.
ABSTRACT The field of gene editing has evolved rapidly over the past decade, progressing from programmable zinc‐finger nucleases (ZFNs) and transcription activator‐like effector nucleases (TALENs) to the widespread adoption of CRISPR‐Cas systems. First‐generation editors catalyzed genome engineering by introducing targeted double‐strand breaks (DSBs ...
Li‐Kuang Tsai, Youcai Xiong, Dongqi Liu, Dongshan Yang, Jifeng Zhang, Jie Xu, Renzhi Han, Y. Eugene Chen   +7 more
wiley   +1 more source

Downregulation of Cyclin Kinase Inhibitors p16INK4a and p27 in Conjunctival Melanomas. [PDF]

Invest Ophthalmol Vis Sci
Sarrasin E, Lalys E, Nardou K, Celik E, Quinodoz M, Schalenbourg A, Riggi N, Rivolta C, Berger A, Moulin A.   +9 more
europepmc   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source

Response of <i>Escherichia coli</i> chemotaxis pathway to pyrimidine deoxyribonucleosides. [PDF]

Microbiol Spectr
Shah M, Xu W, Sourjik V.
europepmc   +1 more source

Deoxycytidine kinase (DCK) [PDF]

Science-Business eXchange, 2014
openaire   +1 more source

CRISPR Enabled Precision Oncology: From Gene Editing to Tumor Microenvironment Remodeling

Med Research, Volume 2, Issue 1, Page 106-129, March 2026.
CRISPR technology has progressed from a prokaryotic immune system to a diverse suite of editing platforms, including Cas nucleases, base and prime editors, and RNA‐targeting enzymes. These advances enable precise genomic and epigenomic interventions, high‐throughput functional screening, and immune engineering.
Kailai Li, Peixin Huang, Yue Qian, Anqi Lin, Jingjun He, Junyi Shen, Li Chen, Kai Miao, Jian Zhang   +8 more
wiley   +1 more source

Local Anesthetics in Cancer: Mechanisms and Translational Perspectives

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Local anesthetics demonstrate multifaceted antitumor effects that collectively contribute to cancer suppression. Beyond canonical sodium channel blockade, these agents exert the following pharmacological actions: inhibition of tumor cell proliferation, suppression of migration and invasion, induction of proapoptotic pathways, attenuation of ...
Wan‐li Wang, Tu Huang, Yi‐hang Hao, Min Zheng, Xin‐hua Liang   +4 more
wiley   +1 more source

Urinary Metabolomic Changes and Potential Exercise-Induced Muscle Damage Biomarkers Identification in Trained Young Males Following Acute Intermittent Rowing Training. [PDF]

Biosensors (Basel)
Cheng Y, Yi Y, Shi X, Bo S.
europepmc   +1 more source

Physiologically Based Pharmacokinetic Virtual Twin Approach for Fludarabine Dosing in Pediatric Hematopoietic Stem Cell Transplantation

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Fludarabine (Flu), administered as a prodrug Flu monophosphate, is a lymphodepleting agent used prior to hematopoietic stem cell transplantation (HSCT) which exhibits substantial pharmacokinetics (PK) variability, contributing to suboptimal outcomes.
Mourad Mseddi, Christa Nath, Khalil Ben Hassine, Vid Mlakar, Yvonne Gloor, Fanny Gonzales, Chakradhara Rao S. Uppugunduri, Youssef Daali, Steven Keogh, Marc Ansari   +9 more
wiley   +1 more source

ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer. [PDF]

Cell Death Dis
Li Y, Wang H, Chen L, Gong Y, Zheng D, Li F, Wu C, He Z, Yu C.   +8 more
europepmc   +1 more source